As early as 2013, we have known that a lower baseline prostate-specific antigen (PSA) is associated with a higher overall survival benefit from Provenge (sipuleucel-T)
Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
Through the work of Huggins et al.  in 1941, it was shown that metastatic prostate cancer responds positively to an orchiectomy (surgical castration). We now know that there isn’t any other therapy which produces a more reliable regression of both distant and local disease than androgen withdrawal (ADT).
Having positive lymph node metastasis (LNM or pN1) after a radical prostatectomy (RP) to treat prostate cancer is a poor prognostic indicator. Knowing what the next best course of treatment is if you are in this situation remains questionable. To begin to understand and better answer this problem a group of researchers performed a comparative analysis of three of the current management strategies for men with positive lymph nodes after RP.
If you have a recurrence of your prostate cancer after primary radiation therapy can a salvage radical prostatectomy (SRP) provide you with any benefits?